Impact of prescribing guidelines for inpatient anticoagulation

被引:10
作者
Schumock, GT
Blackburn, JC
Nutescu, EA
Walton, SM
Finley, JM
Lewis, RK
机构
[1] Univ Illinois, Ctr Pharmacoecon Res, Chicago, IL USA
[2] Univ Illinois, Dept Pharm Practice, Chicago, IL USA
[3] Univ Illinois, Dept Pharm Adm, Chicago, IL USA
[4] Mercy Resource Management Inc, Serv Pharm, Naperville, IL USA
关键词
anticoagulants; costs; low-molecular-weight heparins; medication use evaluation; outcomes; prescribing guidelins;
D O I
10.1345/aph.1E121
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Anticoagulants are widely used and represent a class of drugs that are problem-prone and have a high potential for adverse patient outcomes. As such, these drugs may be amenable to the use of prescribing guidelines. However, relatively little has been published on the effect of such guidelines on clinical outcomes or costs of care. OBJECTIVE: To assess whether guidelines improve the appropriateness of prescribing, clinical outcomes, and costs associated with use of anticoagulants in a sample of community hospitals in the US. METHODS: A retrospective analysis was performed of data voluntarily collected by 15 hospitals before (July-September 2001) and after (March-May 2002) implementation of anticoagulant prescribing guidelines. Statistical analyses of both patient- and hospital-level variables were conducted. RESULTS: Implementation of the guidelines resulted in a significant increase in the proportion of anticoagulants that were prescribed appropriately (59.8% vs 86.9%; p < 0.001). The guidelines also resulted in a shift in the type of anticoagulants prescribed (decreased use of unfractionated heparin and increased use of low-molecular-weight heparins). There was suggestive evidence, although not statistically significant, that the guidelines resulted in fewer anticoagulant-associated adverse events (total bleeding RR 0.71) and lower costs (savings of $56.15 per patient per day). CONCLUSIONS: While limitations existed with the study design, sufficient benefits were identified to warrant hospitals to consider use of these or similar guidelines on a routine basis. Clearly, additional study in this area would be useful.
引用
收藏
页码:1570 / 1575
页数:6
相关论文
共 22 条
[1]  
*AM HOSP ASS, 2002, AM HOSP ASS GUID
[2]   Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes - A Canadian hospital perspective [J].
Balen, RM ;
Marra, CA ;
Zed, PJ ;
Cohen, M ;
Frighetto, L .
PHARMACOECONOMICS, 1999, 16 (05) :533-542
[3]  
Brox WT, 1996, ORTHOPEDICS, V19, P12
[4]   COMPUTERIZED SURVEILLANCE OF ADVERSE DRUG EVENTS IN HOSPITAL PATIENTS [J].
CLASSEN, DC ;
PESTOTNIK, SL ;
EVANS, RS ;
BURKE, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (20) :2847-2851
[5]  
*CTR MED MED, 2004, PREM HOSP QUAL INC D
[6]   Implementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma [J].
Devlin, JW ;
Tyburski, JG ;
Moed, B .
PHARMACOTHERAPY, 2001, 21 (06) :740-747
[7]   A clinical decision support system for prevention of venous thromboembolism - Effect on physician behavior [J].
Durieux, P ;
Nizard, R ;
Ravaud, P ;
Mounier, N ;
Lepage, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (21) :2816-2821
[8]   Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery [J].
Etchells, E ;
McLeod, RS ;
Geerts, W ;
Barton, P ;
Detsky, AS .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (11) :1221-1228
[9]   Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism [J].
Ganz, DA ;
Glynn, RJ ;
Mogun, H ;
Knight, EL ;
Bohn, RL ;
Avorn, J .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2000, 15 (11) :776-781
[10]   Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis - A cost-effectiveness analysis [J].
Gould, MK ;
Dembitzer, AD ;
Sanders, GD ;
Garber, AM .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (10) :789-+